Lea Latham

1.7k total citations
17 papers, 401 citations indexed

About

Lea Latham is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lea Latham has authored 17 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 8 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lea Latham's work include Organ Transplantation Techniques and Outcomes (7 papers), Prostate Cancer Treatment and Research (6 papers) and Cancer Treatment and Pharmacology (6 papers). Lea Latham is often cited by papers focused on Organ Transplantation Techniques and Outcomes (7 papers), Prostate Cancer Treatment and Research (6 papers) and Cancer Treatment and Pharmacology (6 papers). Lea Latham collaborates with scholars based in Italy, United States and New Zealand. Lea Latham's co-authors include William L. Dahut, James R. Wright, Howard L. Parnes, James L. Gulley, Philip M. Arlen, William D. Figg, Clara C. Chen, Elizabeth C. Jones, Jeanny B. Aragon‐Ching and Yang‐Min Ning and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Urology and Molecular Genetics and Metabolism.

In The Last Decade

Lea Latham

16 papers receiving 388 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lea Latham Italy 9 173 163 113 84 66 17 401
Shinya Maita Japan 10 146 0.8× 137 0.8× 109 1.0× 48 0.6× 22 0.3× 25 370
Evelyn Loyer United States 7 54 0.3× 285 1.7× 149 1.3× 34 0.4× 39 0.6× 11 491
Keith L. Shulman United States 9 62 0.4× 164 1.0× 52 0.5× 28 0.3× 28 0.4× 14 347
A Fontana France 10 89 0.5× 324 2.0× 133 1.2× 39 0.5× 128 1.9× 25 505
Butuo Li China 12 161 0.9× 204 1.3× 74 0.7× 40 0.5× 12 0.2× 38 344
Zhangheng Huang China 12 158 0.9× 136 0.8× 64 0.6× 47 0.6× 8 0.1× 39 381
Jeffrey M. Resnick United States 13 122 0.7× 102 0.6× 86 0.8× 63 0.8× 17 0.3× 25 415
Boyang Chang China 12 94 0.5× 224 1.4× 142 1.3× 76 0.9× 6 0.1× 26 458
Saburo Tsunoda Japan 12 65 0.4× 182 1.1× 171 1.5× 19 0.2× 28 0.4× 29 582
T. Taube Finland 12 162 0.9× 515 3.2× 128 1.1× 25 0.3× 119 1.8× 15 620

Countries citing papers authored by Lea Latham

Since Specialization
Citations

This map shows the geographic impact of Lea Latham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lea Latham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lea Latham more than expected).

Fields of papers citing papers by Lea Latham

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lea Latham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lea Latham. The network helps show where Lea Latham may publish in the future.

Co-authorship network of co-authors of Lea Latham

This figure shows the co-authorship network connecting the top 25 collaborators of Lea Latham. A scholar is included among the top collaborators of Lea Latham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lea Latham. Lea Latham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Xu, Xin, Amy Q. Wang, Lea Latham, et al.. (2017). Safety, pharmacokinetics and sialic acid production after oral administration of N -acetylmannosamine (ManNAc) to subjects with GNE myopathy. Molecular Genetics and Metabolism. 122(1-2). 126–134. 44 indexed citations
2.
Gulley, James L., Philip M. Arlen, Sukyung Woo, et al.. (2010). Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 28(12). 2070–2076. 114 indexed citations
3.
Aragon‐Ching, Jeanny B., Yang‐Min Ning, Clara C. Chen, et al.. (2009). Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents. Cancer Investigation. 27(2). 221–226. 106 indexed citations
4.
Ning, Y., Philip M. Arlen, James L. Gulley, et al.. (2008). Phase II trial of thalidomide (T), bevacizumab (Bv), and docetaxel (Doc) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC). Journal of Clinical Oncology. 26(15_suppl). 5000–5000. 14 indexed citations
5.
Figg, William D., Haiqing Li, Tristan M. Sissung, et al.. (2007). Pre‐clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen‐independent prostate cancer. British Journal of Urology. 99(5). 1047–1055. 34 indexed citations
6.
Ning, Y., Philip M. Arlen, James L. Gulley, et al.. (2007). A phase II trial of thalidomide, bevacizumab, and docetaxel in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). Journal of Clinical Oncology. 25(18_suppl). 5114–5114. 17 indexed citations
7.
Aragon‐Ching, Jeanny B., Y. Ning, Lea Latham, et al.. (2007). Osteonecrosis of the jaw (ONJ) in androgen-independent prostate cancer (AIPC) patients receiving ATTP (bevacizumab, docetaxel, thalidomide, and prednisone). Journal of Clinical Oncology. 25(18_suppl). 19594–19594. 3 indexed citations
8.
Ning, Y., Philip M. Arlen, James L. Gulley, et al.. (2006). A phase II trial of docetaxel, thalidomide, bevacizumab, and prednisone in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). Journal of Clinical Oncology. 24(18_suppl). 13037–13037. 5 indexed citations
9.
Retter, Avi S., Philip M. Arlen, James L. Gulley, et al.. (2005). A phase II trial of docetaxel (D), estramustine (E) and thalidomide (T) in patients with metastatic androgen-independent prostate cancer (AIPC). Journal of Clinical Oncology. 23(16_suppl). 4764–4764. 1 indexed citations
10.
Bergamaschini, Luigi, Stefano Gatti, L. Caccamo, et al.. (2001). C1 inhibitor potentiates the protective effect of organ preservation solution on endothelial cells during cold storage. Transplantation Proceedings. 33(1-2). 939–941. 8 indexed citations
11.
Orsenigo, R., et al.. (2001). FK506 and SMS 201-995: effect on heterotopic heart transplantation in rats. Transplantation Proceedings. 33(1-2). 554–555. 1 indexed citations
12.
Maggi, U., L. Caccamo, Stefano Gatti, et al.. (2000). Celsior solution and clinical liver transplantation. Transplantation Proceedings. 32(1). 36–37. 30 indexed citations
13.
Rossi, G., Martin Langer, U. Maggi, et al.. (1998). Veno-venous bypass versus no bypass in orthotopic liver transplantation: hemodynamic, metabolic, and renal data. Transplantation Proceedings. 30(5). 1871–1873. 15 indexed citations
14.
Gatti, Stefano, et al.. (1998). Graft-versus-host reaction and graft rejection after liver, small bowel or small bowel allotransplantation in the pig. Transplantation Proceedings. 30(6). 2601–2604. 1 indexed citations
15.
Maggi, U., G. Rossi, Alberto Vannelli, et al.. (1998). Hepatitis B and C virus–induced diseases and acute rejection after liver transplantation. Transplantation Proceedings. 30(8). 3946–3947.
16.
Reggiani, P., G. Rossi, Lea Latham, et al.. (1998). Reduced acute rejection after liver transplantation with neoral-based double immunosuppression. Transplantation Proceedings. 30(5). 1855–1856. 2 indexed citations
17.
Rossi, G., Stefano Gatti, P. Reggiani, et al.. (1997). Small bowel transplantation under oral immunosuppression: Experimental study in the pig. Transplantation Proceedings. 29(3). 1816–1818. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shinya Maita Breakdown of academic impact, for papers by Evelyn Loyer Breakdown of academic impact, for papers by Keith L. Shulman Breakdown of academic impact, for papers by A Fontana Breakdown of academic impact, for papers by Butuo Li Breakdown of academic impact, for papers by Zhangheng Huang Breakdown of academic impact, for papers by Jeffrey M. Resnick Breakdown of academic impact, for papers by Boyang Chang Breakdown of academic impact, for papers by Saburo Tsunoda Breakdown of academic impact, for papers by T. Taube
Rankless by CCL
2026